Evolocumab Subcutaneous Injection bulk supplier for pharma manufacturers

Evolocumab Subcutaneous Injection 140 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Subcutaneous Injection

Available Strengths: 140 mg/mL

Reference Brands: Repatha(US & EU)

Evolocumab is a monoclonal antibody that inhibits PCSK9, increasing LDL receptor availability to clear LDL cholesterol from the blood. It effectively lowers LDL cholesterol levels, reduces cardiovascular risk, and supports long-term lipid management. Benefits include significant LDL reductions, improved heart health, and prevention of atherosclerotic events.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Evolocumab, marketed as Repatha, is approved in the US by the FDA and in the EU via EMA for lowering LDL cholesterol in patients with familial hypercholesterolemia or cardiovascular disease. Regulatory approval requires a detailed dossier including clinical trial efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews comprehensive clinical and quality documents, while the EMA assesses regional safety and manufacturing compliance. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring regional adherence supports timely approval, safe use, and global availability of evolocumab, helping improve cardiovascular health outcomes worldwide.

Evolocumab Subcutaneous Injection — third party manufacturing & bulk supply

Evolocumab Subcutaneous Injection 140 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Evolocumab Subcutaneous Injection is supplied as Subcutaneous Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Evolocumab Subcutaneous Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Evolocumab Subcutaneous Injection →

Back to Listing

Frequently Asked Questions

Evolocumab Subcutaneous Injection is listed as Subcutaneous Injection in 140 mg/mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Evolocumab Subcutaneous Injection is referenced against Repatha(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.